Aeglea BioTherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AGLE and buy or sell other stocks, ETFs, and their options commission-free!About AGLE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
CEOCameron Turtle, PhD
CEOCameron Turtle, PhD
Employees65
Employees65
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2013
Founded2013
Employees65
Employees65
AGLE Key Statistics
Market cap714.81M
Market cap714.81M
Price-Earnings ratio-15.90
Price-Earnings ratio-15.90
Dividend yield—
Dividend yield—
Average volume799.12K
Average volume799.12K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$34.96
52 Week high$34.96
52 Week low$10.91
52 Week low$10.91
Stock Snapshot
The current Aeglea BioTherapeutics(AGLE) stock price is $11.75, with a market capitalization of 714.81M. The stock trades at a price-to-earnings (P/E) ratio of -15.90.
On 2025-12-09, Aeglea BioTherapeutics(AGLE) stock opened at —, reached a high of —, and a low of —.
The Aeglea BioTherapeutics(AGLE)'s current trading volume is 0, compared to an average daily volume of 799.12K.
In the last year, Aeglea BioTherapeutics(AGLE) shares hit a 52-week high of $34.96 and a 52-week low of $10.91.
In the last year, Aeglea BioTherapeutics(AGLE) shares hit a 52-week high of $34.96 and a 52-week low of $10.91.
People also own
Based on the portfolios of people who own AGLE. This list is generated using Robinhood data, and it’s not a recommendation.